GlobeNewswire

Aino Health AB (publ): The Offer in Aino Health AB (publ) heavily oversubscribed

Dela

PRESS RELEASE
December 9, 2016

NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO NEWS DISTRIBUTORS IN THE UNITED STATES, OR FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR PUBLICATION WOULD NOT BE ALLOWED BY APPLICABLE LAW.
  
Aino Health AB (publ) ("Aino Health" or the "Company") has completed the Offer to the market to subscribe for shares in the Company for a total of 53.8 MSEK (the "Offer"), distributed on a share issue of 46.8 MSEK (the "Share Issue") and an Over-allotment of existing shares of 7.0 MSEK for stabilization activities (the "Over-allotment"). The Over-allotment including stabilization of the share price during 30 calendar days may imply that Aino Health will receive an addition of 7.0 MSEK through a share issue included in the Over-allotment option directed to Erik Penser Bank AB, after which the Company would receive up to 48.8 MSEK.  

The Offer attracted strong interest and was subscribed to about 206 percent, equivalent to 2.1 times the Offer. Due to the strong interest shares have been allocated to around 1 100 new shareholders among almost 4 000 applicants. First day of trading Aino Health's shares is scheduled for Friday December 16, 2016.

November 27, 2016, the Board of Directors in Aino Health published the decision to apply for listing of the Company's shares on Nasdaq First North, and in connection with the listing the Board of Directors decided to diversify the ownership through a Share Issue according to the Offer. The Offer consists of 1,800,000 newly issued shares and an Over-allotment of 270,000 existing shares as a part of the stabilization of the share price during 30 calendar days. The Company may receive an addition of 270,000 shares through the Over-allotment option directed to Erik Penser Bank as a part of the agreed stabilization of the share price.

The number of shares will increase from 3,622,770 to 5,422,770 through the Share Issue and up to 5,692,770 shares if the Over-allotment is fully exercised. The dilution for existing shareholders amounts to 33.2 percent and to a maximum of 36.2 percent if the Over-allotment option is fully exercised.

The Offer implies that the Company will be added around 1 100 new shareholders, after which the total number of shareholders will amount to approximately 1 200. The Company will meet the share distribution requirements on Nasdaq First North and the first day of trading is scheduled for Friday December 16, 2016.

The subscription period for the Offer expired on Thursday, December 8, 2016. A number of institutional partners and private investors have, before the initiated subscription period, undertaken to subscribe for shares in the Share Issue corresponding to approximately 31.9 MSEK, or about 86 percent of the Share Issue.

The Board of Directors in Aino Health has, in consultation with Erik Penser Bank, decided on the allotment of shares in the Offer, in which the objective has been to achieve a good distribution of the share to enable a regular and liquid trading on Nasdaq First North as well as achieving a desired strategic ownership base. The allotment decision will be obtained in the form of a contract note. Information will not be sent to those who have not been allotted shares.

After the Offer has been registered at the Swedish Companies Registration Office the total number of shares in Aino Health will increase by 1,800,000 shares from 3,622,770 shares to 5,422,770 shares. The share capital will increase by 4,500,000 SEK to 13,556,925 SEK. If the Over-allotment option is fully exercised, this implies an additional increase of 270,000 shares and an increase of the share capital of 675,000 SEK to 14,231,925 SEK.

"We are very pleased with the great interest we have had in Aino Health's IPO. While we have secured capital for our expansion into Europe with focus on Sweden and Germany as the first countries, we have received a large number of new shareholders. We are very happy for this and the legitimacy that our listing gives in various customer contacts", says Jyrki Eklund, CEO of Aino Health

Advisers
Erik Penser AB is the financial advisor and Advokatfirman Lindahl KB is the legal adviser in the Offer and listing on Nasdaq First North. Erik Penser AB is Certified Adviser to the Company.

Important information
Publication and distribution of this press release may in certain jurisdictions be restricted by law and persons in those jurisdictions where this press release has been published or distributed should inform themselves about and follow such restrictions. The information in this press release is not an offer to acquire, subscribe for or otherwise trade in shares or another security in Aino Health.

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or another country where such action requires further measures in addition to what follows from Swedish law or where this would contravene with laws or regulations of that country. The information in this press release may not be forwarded, reproduced or disclosed in ways that conflict with such restrictions. Omission to follow this instruction may constitute a violation of the United States Securities Act of 1933 (the "Securities Act") in its present terms or applicable laws in other jurisdictions.

This information is such information that Aino Health AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at December 9 CET on 8:30 2016.

F or more information, please contact:
Jyrki Eklund, CEO
Phone: +358 40 042 4221
E-mail: jyrki.eklund@ainohealth.com

Cecilia Hollerup, Chairman of the Board of Directors
Phone: +46 70 829 33 36
E-mail: cecilia.hollerup@holleruppartners.se

About Aino Health
Aino Health operates within Corporate Health Management. The company has developed a complete system of IT-based services with a focus to improve corporate health and reduce sickness absence levels in private and public organizations.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aino Health AB (publ) via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum